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The molecular mechanisms of chronic pain are
poorly understood and effective mechanism-based
treatments are lacking. Here, we report that mice
lacking adenosine deaminase (ADA), an enzyme
necessary for the breakdown of adenosine, dis-
played unexpected chronic mechanical and thermal
hypersensitivity due to sustained elevated circu-
lating adenosine. Extending from Ada/ mice, we
further discovered that prolonged elevated adeno-
sine contributed to chronic pain behaviors in two
additional independent animal models: sickle cell
disease mice, a model of severe pain with limited
treatment, and complete Freund’s adjuvant paw-in-
jected mice, a well-accepted inflammatory model of
chronic pain. Mechanistically, we revealed that acti-
vation of adenosine A2B receptors on myeloid cells
caused nociceptor hyperexcitability and promoted
chronic pain via soluble IL-6 receptor trans-
signaling, and our findings determined that pro-
longed accumulated circulating adenosine contrib-
utes to chronic pain by promoting immune-neuronal
interaction and revealedmultiple therapeutic targets.INTRODUCTION
Acute pain is beneficial for the organism under dangerous condi-
tions and is relatively well controlled by available analgesics. In
contrast, chronic pain is often debilitating and treated inade-
quately. As the most common chronic medical disorder and
one commonly treated with highly addictive drugs, chronic
pain incurs enormous clinical, economic, and social costs (Ger-
eau et al., 2014; Goldberg and McGee, 2011).There is an urgent
need to define critical molecular mechanisms that may disclose
therapeutic targets for better treatment of chronic pain.106 Cell Reports 16, 106–119, June 28, 2016 ª 2016 The Author(s).
This is an open access article under the CC BY-NC-ND license (http://Chronic pain is associated with numerous clinical conditions,
often having an inflammatory component (Chiu et al.,
2012).Diverse cell types in the peripheral and CNSs, immune
system, and other tissues have been implicated in the induction
and maintenance of chronic pain. Particular attention has been
paid to primary sensory neurons that have their cell bodies in
dorsal root ganglia (DRG).These neurons detect mechanical,
thermal, and chemical stimuli in most tissues, including skin,
muscle, joints, and viscera, and they convey this information
from the periphery to the spinal cord and brain. Sensory neurons
detection of injury has been linked to many chronic pain condi-
tions involving inflammation (Gold and Gebhart, 2010).While
several pathways signaling to nociceptors have been implicated
in inflammatory models (Ji et al., 2014; McMahon et al., 2015),
the signaling pathways critical for inducing chronic inflammatory
pain are not yet fully defined.
Extracellular adenosine is a purinergic ligand, induced by hyp-
oxia and tissue injury, that signals via four G protein coupled re-
ceptors recognized as (ADORA1, ADORA2A, ADORA2B, and
ADORA3) to regulate multiple cellular and systemic functions un-
der physiological and pathological conditions (Fredholm, 2007;
Fredholm et al., 2001). Acutely elevated adenosine signaling
via specific receptors is considered beneficial, producing vaso-
dilation and reducing inflammation and vascular leakage (Eltz-
schig et al., 2003, 2006; Hershfield, 2005). In contrast, persis-
tently elevated adenosine has detrimental effects, promoting
chronic inflammation, tissue fibrosis, andmultiple organ damage
(Dai et al., 2011; Figler et al., 2011; Karmouty-Quintana et al.,
2012; Zhang et al., 2011; Zhang and Xia, 2012).Supporting the
beneficial role of acutely increased adenosine, early studies
showed that acutely elevated adenosine signaling via peripheral
and spinal ADORA1 inhibits pain-related behavior (Aley et al.,
1995; Goldman et al., 2010; Wu et al., 2005). Additional studies
showed that acute actions of adenosine via peripheral
ADORA2A can sensitize pain-related behavior (Li et al., 2010;
Taiwo and Levine, 1990). The role of sustained elevated adeno-
sine in chronic pain remained unclear and cannot be fully under-
stood using animal models with brief and transient elevation of
adenosine. As a result, the underlying mechanism through whichcreativecommons.org/licenses/by-nc-nd/4.0/).
adenosine signaling contributes to chronic pain may be more
complex than once thought and remains poorly understood.
We demonstrated that sustained elevated blood adenosine
plays an unexpectedly major role in the development of pain-
related behavioral responses in three distinct chronic pain
models. Mechanistically, we revealed that prolonged elevated
extracellular adenosine specifically activates ADORA2B on
myeloid cells, subsequently transactivates nociceptors of sen-
sory neurons, and eventually causes hypersensitive neurons
and chronic pain in an IL-6 and sIL-6R trans-signaling-depen-
dent manner. Our findings reveal that sustained elevated circu-
lating adenosine coupled with ADORA2B plays a major role in
chronic pain by promoting immune-neuronal interaction and
suggests therapeutic targets to counteract chronic pain.
RESULTS
ADA-Deficient Mice Display Chronic Pain Behavior due
to Sustained Elevation of Circulating Adenosine
ADA deficiency in humans and mice is lethal due to severe purine
metabolic disturbances. Fortunately, polyethylene glycol-ADA
(PEG-ADA) enzyme therapy isused to treatADA-deficient humans
and mice to prevent mortality by lowering, but not eliminating the
accumulation of adenosine (Blackburn et al., 2000; Hershfield,
1995). We routinely inject PEG-ADA weekly into Ada/ mice
frombirth to prevent excessive elevation of adenosine tomaintain
them alive. Surprisingly, we observed that Ada/ mice were un-
usually more agitated and aggressive compared to Ada/+ litter-
mates when we injected them with PEG-ADA, suggesting that
these mice might experience chronic pain. As expected, without
continuous PEG-ADA treatment and only with PBS, we found
theplasmaadenosine began to increaseonday 2, continued to in-
crease on day 4, peaked around day 8, and remained high at
2 weeks (Figure 1A). The rise in adenosine after stopping PEG-
ADA treatment was accompanied with significantly increased
sensitivity to both thermal andmechanical stimuli from day 2 (Fig-
ures 1Band 1C). An additional increase in response to both stimuli
was observed on days 4–8, with a further increase on day 14 (Fig-
ures 1B and 1C). In contrast, to keep constant low adenosine
within a 2-week experimental period, we injected PEG-ADA every
other day instead of weekly prior to our pain behavior measure-
ment. Ada/ mice receiving continuous PEG-ADA treatment
maintainedmuch lower levels of plasma adenosine and displayed
no significant pain behavior (Figures 1A–1C). Overall, our findings
provide solid genetic evidence that prolonged elevation of circu-
lating adenosine contributes to chronic sensory hypersensitivity
in Ada/ mice. More importantly, Ada/ mice are a genetic
tool to further dissect themolecular basis of chronic pain resulting
from prolonged elevated adenosine.
ADORA2B Is Essential for Adenosine-Induced Chronic
Pain in Ada/ Mice
To determine which adenosine receptors are responsible for
adenosine-induced pain behavior in Ada/ mice, we initially
took a pharmacological approach. Briefly, we treated Ada/
mice for 2 weeks with PBS or four different antagonists specific
for each type of adenosine receptor. Moreover, wild-type (WT)
mice were treated with PBS as the control. First, we found thatAda/ mice treated with PBS showed increased sensitivity to
stimuli compared to the WT mice treated with PBS (Figures 1D
and 1E). Moreover, among four specific adenosine receptor an-
tagonists, only the ADORA2B-specific antagonist, PSB1115,
significantly reduced mechanical and thermal hypersensitivity
in the Ada/ mice (Figures 1D and 1E), suggesting that
ADORA2B is particularly important for adenosine-induced
chronic pain in Ada/ mice.
To validate our pharmacological findings, we generated
Ada//Adora2b/ mice (Iriyama et al., 2015). As expected,
the plasma adenosine levels were increased to a similar level
in both Ada//Adora2b/ and Ada//Adora2b/+ mice
without PEG-ADA treatment (Figure 1F). Supporting our pharma-
cological studies, genetic deletion of ADORA2B in Ada/ mice
significantly attenuated hypersensitivity (Figures 1G and 1H).The
pharmacological and genetic evidence led us to conclude that
ADORA2B is essential for pain behavior in response to persis-
tently increased adenosine in the Ada/ mice.
Adenosine-ADORA2B Signaling Produces
Hyperexcitability in Sensory Neurons of ADA-Deficient
Mice
Hyperexcitable sensory neurons play a major role in driving
many kinds of persistent pain (Basbaum et al., 2009; Gold and
Gebhart, 2010; Walters, 2014). Supporting this notion, we found
that the action potential threshold (rheobase) during prolonged
depolarizing pulses was significantly reduced in the sensory
neurons isolated from DRG of Ada/ compared to Ada/+
mice (Figure 1I). Treatment with PEG-ADA or PSB1115 normal-
ized action potential threshold in DRG neurons of the Ada/
mice (Figure 1I). These results show that a prolonged increase
in adenosine-ADORA2B signaling enhances the excitability of
primary sensory neurons and likely contributes to chronic pain
in the Ada/ mice.
Elevated Circulating Adenosine Signaling via ADORA2B
Induces Hypersensitivity of Nociceptors and Underlies
Chronic Pain in Sickle Cell Disease Mice
We have previously shown that elevated plasma adenosine in
humans and mice with sickle cell disease (SCD) contributes to
sickling, the central pathogenic process of the disease, by acti-
vating ADORA2B on erythrocytes (Zhang et al., 2011). However,
a role for ADORA2B signaling in SCD pain has not been ad-
dressed. Based on our findings that elevated adenosine contrib-
utes to chronic pain via activation of ADORA2B in Ada/ mice,
we hypothesized that elevated circulating adenosine may
contribute to chronic pain in SCD by inducing hyperexcitability
of nociceptive sensory neurons. To test this hypothesis, we
took advantage of SCD mice, a well-accepted humanized
mouse model that exhibits chronic-pain-like behavior. First, we
found that action potential threshold (rheobase) was significantly
reduced in DRG neurons isolated from SCD mice compared to
control (Figure 2A). Next, we treated SCD mice with or without
PEG-ADA or PSB1115 for 2 weeks to examine whether elevated
adenosine-ADORA2B signaling is responsible for sensory
neuron hyperexcitability. Similar to Ada/ mice, we found that
PEG-ADA treatment significantly reduced adenosine levels in
the plasma of SCD mice (Figure 2B). Moreover, PEG-ADA orCell Reports 16, 106–119, June 28, 2016 107
Figure 1. Ada /MiceDisplay Reflex Hypersensitivity andHyperexcitable Sensory Neurons after Prolonged Adenosine-ADORA2B Signaling
(A) Plasma adenosine levels in the Ada+/ and Ada/ mice treated with PBS or PEG-ADA every other day for 2 weeks (*p < 0.01, n = 6).
(B and C) Pawwithdrawal threshold tomechanical and thermal test stimuli were lower inAda/ compared toAda/+ mice (*p < 0.01, n = 10). PEG-ADA treatment
prevented mechanical and thermal hypersensitivity in Ada/ (*p < 0.001, n = 10).
(D and E) Hypersensitivity were observed in Ada/ compared toWTmice treated with PBS. However, hypersensitivity in Ada/mice were prevented by 2 week
treatment with an ADORA2B antagonist, PSB1115, but not by other adenosine receptor antagonists (*p < 0.001, n = 10).
(F) PEG-ADA treatment normalized plasma adenosine in Ada/ and Ada//Adora2b/ mice (*p < 0.05, **p < 0.01, n = 6).
(G and H) Mechanical and thermal hypersensitivity was attenuated in Ada//Adora2b/ mice (*p < 0.05, **p < 0.01, n = 6).
(I) Action potentials evoked by depolarizing test currents in DRG neurons isolated from Ada/ mice previously treated in vivo with or without PEG-ADA or
PSB1115. The threshold current (rheobase) was lower in DRG neurons from Ada/ than Ada/+ mice (*p < 0.01, n = 6). PEG-ADA or PSB1115 treatment in vivo
attenuated sensory neuron hyperexcitability in Ada/ mice (**p < 0.01, n = 5).PSB1115 treatment normalized action potential threshold in sen-
sory neurons of SCD mice (Figure 2A). As expected, the SCD
mice displayed reflex hypersensitivity to both stimuli (Hillery
et al., 2011). Importantly, both the plasma concentration of aden-
osine and the reflex hypersensitivity in SCD mice were signifi-
cantly reduced by PEG-ADA (Figures 2C and 2D). PSB1115
treatment suppressed both mechanical and heat hypersensitiv-
ity without significantly changing the plasma adenosine level
(Figures 2B–2D).The similarity of the effects of PEG-ADA and
PSB1115 on pain-related electrophysiological and behavioral al-108 Cell Reports 16, 106–119, June 28, 2016terations in SCD and Ada/mice indicates a potentially general
role for adenosine-ADORA2B signaling in chronic pain by in-
ducing hyperexcitability in nociceptive sensory neurons.
Upregulated TRPV1 Gene Expression and Function in
DRG Neurons of Both ADA-Deficient and SCD Mice Are
Dependent on Sustained Elevated Adenosine Signaling
via ADORA2B
Enhanced transient receptor potential V1 (TRPV1) channel
plays an important role in multiple forms of chronic pain
Figure 2. Adenosine-ADORA2B Signaling
Contributes to Sensory Neuron Hyperexcit-
ability and Reflex Hypersensitivity in SCD
Mice
(A) Action potential threshold was lower in sensory
neurons from SCD than control SCD/+ mice (*p <
0.01, n = 7). After in vivo treatment with PEG-ADA
or PSB1115 the rheobase increased (**p < 0.01,
n = 7). PBS was used as a control.
(B) Plasma adenosine concentration was in-
creased in SCD mice (*p < 0.01, n = 10). In vivo
treatment with PEG-ADA decreased the adenosine
level (**p < 0.01, n = 8).
(C and D) SCD mice showed hypersensitivity
compared to control mice (*p < 0.01, n = 18). In vivo
PEG-ADA or PSB1115 treatment reduced reflex
hypersensitivity in SCD mice. (**p < 0.01, n =
18–22).including inflammatory pain models (Ji et al., 2002) and re-
flex hypersensitivity in SCD mice (Hillery et al., 2011).
Because we found that adenosine signaling via ADORA2B
contributed to neuronal hypersensitivity and subsequent
chronic pain behavior in both Ada/ and SCD mice, we hy-
pothesized that sustained accumulated circulating adeno-
sine, activating ADORA2B, likely underlies elevated TRPV1
activity. To test this possibility, we first determined whether
adenosine-ADORA2B signaling enhances the sensitivity of
isolated DRG neurons to a highly selective, plant-derived
activator of TRPV1 channels, capsaicin. This was done by
comparing the incidence of neurons responding with detect-
able intracellular Ca2+ transients when stimulated with low
concentration of capsaicin (10 nM). DRG neurons isolated
from Ada/ or SCD mice showed a striking increase in
the incidence of [Ca2+]i responses compared to DRG neu-
rons isolated from control mice, which rarely responded to
this low concentration of capsaicin (Figure 3A). These results
show that a chemical activator of TRPV1 channels is partic-
ularly effective in activating DRG neurons in Ada/ and
SCD mice, but not in control mice, at such a low
concentration.
One potential explanation for hypersensitivity to TRPV1 ac-
tivators would be an increase in the number of TRPV1 chan-
nels expressed by DRG neurons. Thus, we determined if
TRPV1 gene expression is elevated in DRG neurons of Ada/Ceor SCD mice. We found that TRPV1
mRNA in DRGs was significantly
elevated in both Ada/ and SCD mice
compared to the controls (Figure 3B).
Moreover, the increased TRPV1 gene
expression in DRG of Ada/ or SCD
mice was significantly reduced by
lowering adenosine levels with PEG-
ADA or by blocking ADORA2B with
PSB1115 for 2 weeks (Figures 3B and
3C). These results demonstrate that pro-
longed adenosine-activated ADORA2B
signaling induces TRPV1 gene expres-sion and promotes its function in nociceptors of both Ada/
and SCD mice.
IL-6 Functions Downstream of ADORA2B Signaling to
Promote Sensory Neuronal TRPV1 Channel
Hyperexcitability and Reflex Hypersensitivity in Ada/
and SCD Mice
Next, we investigated whether ADORA2B signaling directly acti-
vates nociceptors of DRG sensory neurons by applying NECA, a
non-metabolized adenosine analog, directly to (WT) mouse DRG
neurons. Unexpectedly, NECA did not induce a measurable
[Ca2+]i response (Figure 3D). Similarly, we did not observe a
[Ca2+]i response upon treatment with the ADORA2B-specific
agonist, BAY 60-6583 (Figure 3E), although capsaicin induced
a robust [Ca2+]i response in these cells (Figures 3D and 3E).
Moreover, we found thatAdora2bmRNA levels weremuch lower
in DRG neurons isolated from controls than in the lung tissue as a
positive control (Figure 3F). Furthermore, Adora2b mRNA was
barely detectable in theDRGsofAda/or SCDmice (Figure 3G).
Therefore, both biochemical and functional observations sug-
gest that enhanced TRPV1 expression and function in DRG neu-
rons are not caused by acute and direct activation of ADORA2B
in either Ada/ or SCD mice.
Elevated circulating IL-6 is associated with inflammation and
chronic pain in both Ada/ and SCD mice (Dai et al., 2011;
Zhang et al., 2011), and IL-6 is involved in persistentll Reports 16, 106–119, June 28, 2016 109
Figure 3. Adenosine-Induced Elevated TRPV1 Gene Expression, Calcium Influx, and Nociceptive Hypersensitivity in Ada/ and SCD Mice
Are Not Directly Mediated by Activation of ADORA2B on DRG Sensory Neuronal Cells
(A) Incidences of neurons with calcium responses to 10 nM capsaicin were higher in DRG neurons isolated from Ada/ and SCD mice than DRG neurons from
Ada/+ or SCD/+ (*p < 0.01, n = 5–7) (#p < 0.01).
(B and C) TRPV1 gene expression was increased in DRG from Ada/ and SCDmice compared to controls (*p < 0.01, n = 7–8) and the increased expression was
attenuated by PEG-ADA or PSB1115 (**p < 0.01, n = 7–8).
(D and E) Adenosine receptor agonists NECA and BAY 60-6583 failed to evoke calcium responses in DRG neurons.
(F) qRT-PCR indicates thatAdora1 is themajor adenosine receptor expressed in DRG neurons ofWTmice, with the other three adenosine receptors expressed at
much lower levels (*p < 0.05, n = 3).
(G) Expression of Adora2b mRNA in DRG isolated from Ada/ and SCD mice. Lung tissue is a positive control.inflammatory pain in humans and in preclinical models (Dina
et al., 2011; Murphy et al., 1999; Nishimoto et al., 2009). It is
possible that increased IL-6 is a common molecule functioning
downstream of ADORA2B signaling underlying elevated circu-
lating adenosine-induced nociceptor TRPV1 expression and
excitability in Ada/ and SCD mice. To test this possibility,
we first measured circulating IL-6 in both Ada/ and SCD
mice treated with or without PEG-ADA or PSB1115 for 2 weeks.
As expected, plasma IL-6 levels were significantly elevated in110 Cell Reports 16, 106–119, June 28, 2016Ada/ and SCD mice and PEG-ADA or PSB1115 treatment
significantly reduced elevated circulating IL-6 in both Ada/
and SCD mice (Figure 4A). These results indicate that pro-
longed exposure to high levels of adenosine enhances IL-6
release in both Ada/ and SCD mice through ADORA2B
signaling. We further investigated whether increased circulating
IL-6 contributes to chronic pain in Ada/ using an IL-6 neutral-
izing antibody. Strikingly, a 2-week treatment with IL-6 neutral-
izing antibody significantly reduced both mechanical and
Figure 4. IL-6 Trans-signaling via sIL-6R Promotes Reflex Hypersensitivity and Sensory Neuron Hyperexcitability in Ada/ and SCD Mice
(A) Plasma IL-6 levels were significantly elevated in Ada/ and SCD mice compared with controls (*p < 0.01), and the elevated IL-6 concentrations were
decreased by in vivo treatment with PEG-ADA or PSB1115 (**p < 0.01, n = 8).
(B and C) In vivo treatment with neutralizing IL-6 antibody in Ada/ or genetic deletion of IL-6 in SCD mice reduced hypersensitivity (*p < 0.01, n = 12 in each
case).
(D) The incidence of DRG neurons responding to 10 nM capsaicin was reduced in Ada/ mice treated with neutralizing IL-6 antibody and in SCD/IL-6/ mice
(*p < 0.01, n = 8 in each case).
(E) Plasma sIL-6R levels were increased in Ada/and SCD mice (*p < 0.01), and the elevated sIL-6R levels were reduced by PEG-ADA or PSB1115 treatment
(**p < 0.01, n = 8).
(F and G) Sgp130Fc treatment reduced reflex hypersensitivity in Ada/ and SCD mice compared to those treated with isotype IgGFc (*p < 0.01, n = 10).
(H) DRG neurons responding to 10 nM capsaicin was reduced in Ada/ and SCD mice treated with sgp130Fc compared to mice treated with IgGFc (*p < 0.01,
n = 6).
(I) Sgp130Fc treatment reduced TRPV1 mRNA levels in DRG of Ada/ and SCD mice compared to controls treated with isotype IgGFc (*p < 0.01, n = 6).
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thermal reflex hypersensitivity in Ada/ mice (Figures 4B and
4C). Similarly, we found that genetic deletion of IL-6 in SCD
mice significantly reduced reflex hypersensitivity in SCD mice
(Figures 4B and 4C). Finally, the enhanced capsaicin responses
in DRG neurons were significantly attenuated by IL-6 neutral-
izing antibody in Ada/ mice or genetic deletion of IL-6 in
SCD mice (Figure 4D). These studies identify IL-6 as a critical
molecule functioning downstream of ADORA2B to promote
TRPV1 function, sensory hypersensitivity, and pain-related
behavior in two independent animal models.
IL-6 Trans-signaling via the sIL-6R Induces Sensory
Neuronal TRPV1 Channel Hyperexcitability and
Pain-Related Behavior in Ada/ and SCD Mice
Next, we investigated whether IL-6 by itself directly activates
DRG sensory neurons, as suggested in other studies (Dubovy´
et al., 2013; Fang et al., 2015; Leskovar et al., 2000; Wei et al.,
2013). Surprisingly, IL-6 did not induce obvious [Ca2+]i re-
sponses, unlike capsaicin in the same neurons (Figure S1A).
Consistent with this finding, IL-6R mRNA expression levels
were much lower in DRG neurons isolated from control, Ada/,
or SCD mice than in bone marrow derived cells (BMDCs) as a
positive control (Figure S1B). These results led us to conclude
that IL-6 does not induce hyperexcitability by directly and
acutely activating IL-6Rs on DRG neurons. Among all known cy-
tokines, only IL-6 can activate cells lacking IL-6Rs by forming a
complex with sIL-6Rs that transactivates gp130, a ubiquitously
expressed IL-6R cofactor. Given the unique feature of IL-6-sIL-
6R trans-signaling, we immediately hypothesized that IL-6
trans-signaling via sIL-6R underlies ADORA2B-mediated neu-
ronal hyperexcitability in both Ada/ and SCD mice. To test
this possibility, we first measured sIL-6R levels in Ada/ and
SCDmice treated with or without PEG-ADA or PSB1115. Similar
to IL-6, we found that circulating sIL-6R levels were significantly
elevated in both Ada/ and SCD mice and the elevated levels
were significantly reduced by PEG-ADA or PSB1115 treatment
(Figure 4E). Next, we determined whether IL-6 could mediate
sensory hypersensitivity in Ada/and SCD mice by IL-6 trans-
activation of gp130 on DRG neurons by treating Ada/ and
SCD mice for 2 weeks with Fc isotype IgG or a specific fusion
antibody to neutralize gp130. We found that reflex hypersensitiv-
ity to both stimuli was substantially reduced in both Ada/ and
SCD mice after gp130 neutralizing antibody treatment (Figures
4F and 4G). The proportion of DRG neurons from either Ada/
or SCDmice that responded to 10 nMcapsaicin was significantly
reduced by treatment with the gp130 neutralizing antibody,
which suppressed TRPV1 gene expression in DRG neurons
(Figures 4H and 4I). Altogether, we demonstrated that IL-6
forms a complex with sIL-6R to transactivate gp130, which in-
creases sensory neuronal TRPV1 expression and function and
thereby contributes to persistent pain in both Ada/ and SCD
mice.
BMDCs Are Responsible for ADORA2B-Mediated
Upregulation of TRPV1 Expression and Chronic Pain in
SCD Mice
Plasma IL-6 and sIL-6R are produced primarily by circulating
BMDCs and/or tissue resident immune cells (Xie et al.,112 Cell Reports 16, 106–119, June 28, 20162006). To determine which immune cells are responsible for
ADORA2B-mediated elevation of plasma IL-6 and sIL-6R levels
and subsequent chronic pain, we conducted bone marrow
transplant (BMT) experiments. Specifically, we transplanted
bone marrow (BM) of SCD mice to irradiated WT or Adora2b/
mice. Sixteen weeks post-BMT, flow cytometry was used to
examine chimeras by quantifying blood CD45.1 and CD45.2
positive cells. As shown in Figure S2A, BMT from SCD to WT
or Adora2b/ mice was very successful with nearly 100% of
circulating cells donor derived. Following successful BMT, we
conductedmechanical and thermal behavioral assays.We found
that WT mice transplanted with BM from SCD mice (SCD-WT
group) displayed mechanical and thermal reflex hypersensitivity
similar to the SCD mice (Figures S2B and S2C). Moreover, we
observed that recipient Adora2b/ mice transplanted with BM
of SCD mice (SCD-Adora2b/) displayed behavioral hypersen-
sitivity similar to SCD-WTmice (Figures S2B and S2C), indicating
that deficiency of ADORA2B in peripheral tissues does not affect
chronic-pain-related behavior in SCD mice. We conclude that
ADORA2B on BMDCs is essential for generating chronic pain
in the SCD mice.
Next, we performed patch-clamp studies on DRG neurons
isolated from both SCD-WT and SCD-Adora2b/ mice to
directly assess nociceptor hyperexcitability. We found that sen-
sory neurons isolated fromSCD-Adora2b/mice showed excit-
ability similar to SCD-WT (Figure S2D). Additionally, we found
that TRPV1 mRNA levels were similar among these mice (Fig-
ure S2E). These studies provide in vivo evidence that elevated
adenosine-ADORA2B signaling in circulating BMDCs contrib-
utes to the upregulation of TRPV1 gene expression and chronic
pain in SCD mice.
ADORA2B in Myeloid Cells Contributes to
Hypersensitivity in a Chronic Inflammatory Pain Model
Myeloid cells maintain the innate immune system and may have
complex involvement in chronic inflammatory pain (Abbadie
et al., 2003; Moalem and Tracey, 2006; Willemen et al., 2014).
To determine the functional role of ADORA2B on myeloid
cells in chronic inflammatory pain, we injected a hind-
paw with CFA, a well-established mouse model of chronic
inflammatory pain, in control mice (Lyz-Cre) and mice in which
ADORA2B was knocked out specifically in myeloid cells
(Adora2bf/fLyz-Cre). Lyz-Cre mice displayed more severe paw
edema than Adora2bf/f-Lyz-Cre mice (Figure S3). Moreover,
Adora2bf/f-Lyz-Cre mice showed CFA-induced reflex hyper-
sensitivity similar to that of Lyz-Cremice during the acute phase
(Figures 5A and 5B), and the Adora2bf/f-Lyz-Cremice displayed
significantly less reflex hypersensitivity compared to the con-
trols during the delayed phase (Figures 5C and 5D), suggesting
that genetic ablation of ADORA2B on myeloid cells reduces
CFA-induced chronic inflammatory pain. No difference of basal
levels of circulating adenosine and IL-6 was observed between
Adora2bf/f-Lyz-Cre and Lyz-Cremice (Figure S4). We found that
CFA induced elevation of plasma adenosine levels, which
reached a peak within 2 hr post-injection and remained
elevated at 6 hr in both control Lyz-Cre and Adora2bf/fLyz-Cre
mice (Figure 5E). We found that CFA increased IL-6 levels in
Lyz-Cre mice within 6 hr and remained elevated for 24 hr
Figure 5. ADORA2B onMyeloid Cells Is Required for ReflexHypersensitivity and Sensory NeuronHyperexcitability Induced in aCFAModel of
Inflammatory Pain
(A–D) Intraplantar injection of CFA induced similar hypersensitivity for the first 3 hr in Lyz-Cre and Adora2bf/f/Lyz-Cremice. From 6 hr to 7 days, CFA induced less
mechanical and heat hypersensitivity in Adora2bf/f/Lyz-Cre mice compared to Lyz-Cre mice (*p < 0.01, n = 6).
(E) CFA injection induced similar changes in plasma adenosine concentration in Lyz-Cre and Adora2bf/f/Lyz-Cre mice (*p < 0.05, n = 3).
(F) CFA injection induced less plasma IL-6 in Adora2bf/f/Lyz-Cre mice compared to Lyz-Cre mice (*p < 0.05, n = 3).
(G) TRPV1 mRNA levels in DRG neurons in CFA-injected Adora2bf/f/Lyz-Cre and Lyz-Cre mice at different time points (*p < 0.05, n = 3).
(H) Action potential thresholds in sensory neurons from Adora2bf/f/Lyz-Cre mice were significantly higher than sensory neurons from Lyz-Cre mice at 6 hr and
7 days post CFA injection (*p < 0.05, n = 3).(Figure 5F). In contrast, genetic ablation of myeloid-cell-spe-
cific ADORA2B significantly attenuated plasma IL-6 levels
compared to control mice 6 and 24 hr after CFA injection
(Figure 5F). Additionally, we found that TRPV1 mRNA levels of
isolated DRG neurons were not significantly different between
Lyz-Cre and Adora2bf/f-Lyz-Cre mice without CFA injection
(Figure 5G). However, TRPV1 mRNA levels were significantly
induced in DRG neurons by CFA in the control mice on day 2
up to day 7, whereas their induction in DRGs isolated from the
Adora2bf/f-LyzCre mice on day 2 and day 7 after CFA injectionwere significantly decreased when compared to Lyz-Cre
mice (Figure 5G). Finally, we confirmed that nociceptor excit-
ability was significantly lower in isolated sensory neurons from
Adora2bf/fLyz-Cre mice than in neurons from control mice 6 hr
and 7 days following CFA injection (Figure 5H). These findings
provide strong evidence that ADORA2B on myeloid cells
is required for IL-6 production in response to elevated levels
of circulating adenosine, along with increased TRPV1 gene
expression and associated hyperexcitability of nociceptors in
this model of chronic inflammatory pain.Cell Reports 16, 106–119, June 28, 2016 113
Figure 6. IL-6 Complexes with sIL-6R to Induce TRPV1 Gene Expression in a STAT3-Dependent Manner in DRG Neurons
(A) Representative immunofluorescence staining of pSTAT3 in DRGs isolated form WT mice treated with control buffer, IL-6, sIL-6R, IL-6+sIL-6R, IL-6+sIL-
6R+gp130Fc, and IL-6+sIL-6R+IgGFc. Right: the fraction of DRG cells stained with pSTAT3 (*p < 0.05, **p < 0.05, n = 6). Scale bar, 50 mm.
(B) TRPV1 mRNA levels were increased in DRG cells isolated from WT mice treated for 24 hr with IL-6+sIL-6R together but not separately. TRPVI mRNA levels
were reduced by pretreatment with gp130Fc or Statics, a pSTAT3 inhibitor (*p < 0.05, **p < 0.01).IL-6 Trans-signaling via the sIL-6R Directly Induces
TRPV1 Gene Expression in DRG Neurons in a
STAT3-Dependent Manner
STAT3 is a key signaling molecule downstream of IL-6R activa-
tion. When STAT3 is phosphorylated, it translocates to the nuclei
and regulates gene transcription. STAT3 might contribute to the
induction of TRPV1 gene expression in primary nociceptors by
the IL-6 trans-signaling pathway. To test the direct involvement
of sIL-6R and gp130 in the induction of TRPV1mRNA in nocicep-
tors, we isolated DRG neurons from WT mice and treated them
with IL-6, sIL-6R, or their combination, either in the presence
or absence of gp130 neutralizing antibody. After 30 min of treat-
ment, cells stained positive for pSTAT3 were slightly, but not
significantly, increased in DRG neurons treated with IL-6 alone
(Figure 6A), consistent with our finding of very low expression
of IL-6R in DRG neurons (Figure S1A). Similarly, sIL-6R alone
had no significant effect. Strikingly, co-administration of IL-6114 Cell Reports 16, 106–119, June 28, 2016and sIL-6R significantly increased pSTAT3 staining in DRG
neuron nuclei. As expected, addition of gp130 neutralizing anti-
body prevented the increase in pSTAT3 nuclear staining stimu-
lated by IL-6 and sIL-6R (Figure 6A). These results indicate that
IL-6 trans-signaling can activate pSTAT3 via sIL-6R to activate
gp130 in DRG neurons.
Next, we assessed the effects of sIL-6R/IL-6-mediated trans-
signaling via pSTAT3 on TRPV1 gene expression in DRG neu-
rons. After 24-hr treatment of dissociated DRG neurons, we
found that TRPV1 gene expression was significantly induced
by combined IL-6 and sIL-6R, but not by IL-6 or sIL-6R alone
(Figure 6B). Moreover, a gp130-neutralizing antibody or specific
inhibitor of pSTAT3 (Statics) significantly suppressed IL-6/sIL-6-
induced TRPV1 gene expression in dissociated DRG neurons
(Figure 6B). These results show that sIL-6R/IL-6 transactivate
gp130 in DRG neurons to induce TRPV1 gene expression in a
pSTAT3-dependent manner.
DISCUSSION
Here, we report that sustained elevated circulating adenosine
signaling via ADORA2B is required for chronic pain behavior
and neuronal hypersensitivity in three independent animal
models, includingAda/, SCD, andCFA-injectedmice. Surpris-
ingly, adenosine-dependent pain behavior did not involve direct
and acute actions of ADORA2B on primary nociceptors. Instead,
elevated adenosine required ADORA2B signaling in myeloid
cells to stimulate sensory hyperexcitability and hypersensi-
tivity through IL-6 and sIL-6R, and consequent trans-activation
of gp130, which stimulates a STAT3-dependent enhancement
of TRPV1 gene expression in DRG neurons. These findings
reveal an unexpectedly important role for prolonged adeno-
sine-ADORA2B signaling in several models of chronic pain and
show that these adenosine effects depend upon IL-6 signaling
from myeloid cells to transactivate sensory neurons.
Adenosine is a signaling molecule induced under hypoxia and
energy depletion and involved inmultiple physiological and path-
ological conditions (Eckle et al., 2014; Eltzschig and Carmeliet,
2011; Mi et al., 2008; Sun et al., 2006; Zhang et al., 2011). Impor-
tantly, acute and prolonged effects of adenosine on injured or
stressed tissues often differ dramatically, with brief exposure
reducing inflammation and prolonged exposure promoting
inflammation (Dai et al., 2011; Iriyama et al., 2015; Karmouty-
Quintana et al., 2012; Reutershan et al., 2009; Schingnitz et al.,
2010; Zhou et al., 2011). A diversity of preclinical models of
pain has illustrated the anti-nociceptive properties of ADORA1
activation (Korboukh et al., 2012; Sowa et al., 2010). In contrast,
the role of ADORA2A in pain has been ambiguous with some
studies showing anti-nociceptive and others showing pro-
nociceptive roles. Moreover, there have been fewer reports
regarding the effects of ADORA2B signaling in nociception, but
in general the observations are consistent with a peripheral
pro-nociceptive role (Abo-Salem et al., 2004; Bastia et al.,
2002; Belikoff et al., 2011; Li et al., 2010). Adenosine either pro-
motes or inhibits nociception depending on the site of action and
the specific receptor involved (Sawynok and Liu, 2003; Sawynok
et al., 1998). Moreover, the reports linking adenosine signaling
and pain have varied according to the preclinical model used
for testing (Sawynok, 2015). Of note, in contrast to the analgesic
effect of local intrathecal activation of ADORA2B by BAY60-
60583 reported by Loram et al. (2013), other early reports
showed that intraperitoneal (IP) injection of ADORA2B antago-
nists reduces pain induced by diphenyl diselenide (Savegnago
et al., 2008) and an acute pain model (Abo-Salem et al., 2004).
However, molecular mechanisms and cell type underlying
ADORA2B antagonism in chronic inflammatory pain remained
unclear prior to our current studies. Supporting early pharmaco-
logical studies showing analgesic effects of IP injection of
ADORA2B antagonists (Abo-Salem et al., 2004; Savegnago
et al., 2008), we consistently showed that IP injection of an
ADORA2B antagonist is analgesic in two independent models
of chronic pain, including Ada/ and SCD mice. Consistent
with pharmacological evidence, we provided genetic evidence
revealing that prolonged accumulation of systemic adenosine
in chronic inflammatory pain by activating ADORA2B signaling
on myeloid cells in both SCD and CFA-injected mice, a chronicinflammatory pain model. Mechanistically, we further revealed
myeloid cell ADORA2B-mediated IL-6 trans-signaling is a previ-
ously unrecognized pathway underlying chronic inflammatory
pain by inducing TRPVI gene expression in neuronal cells of
the DRG in a pSTAT3-dependent manner. Altogether, we re-
vealed that sustained elevated circulating adenosine signaling
via ADORA2B on myeloid cells mediated an IL-6 trans-signaling
cascade that is a mechanism underlying chronic inflammatory
pain, which is different from neuropathic models.
Notably, circulating adenosine is chronically elevated and
contributes to sickling in SCD patients and mice (Zhang et al.,
2011), a humanized model of SCD that exhibits chronic pain by
activating ADORA2B. Moreover, early studies showed that
ADORA2A activation in invariant natural killer (iNK) cells contrib-
utes to reduced pulmonary damage in SCD (Wallace and Linden,
2010). However, a role for adenosine signaling in chronic pain in
SCD had not been recognized until we discovered that Ada/
mice display chronic pain. As we found with Ada/ and SCD
mice in which adenosine levels were lowered by PEG-ADA treat-
ment or ADORA2B signaling was inhibited by a specific receptor
antagonist, we found a significant reduction of pain behavior and
a reversal in DRG neurons of both electrical hyperexcitability and
hypersensitivity to capsaicin. These effects were paralleled by a
reversal of enhanced TRPV1 gene expression found in DRG neu-
rons taken from both Ada/ and SCD mice. These findings are
consistent with the earlier demonstration that pharmacological
inhibition of TRPV1 blocked hypersensitivity of mechanically
evoked reflexes in SCDmice (Hillery et al., 2011).Moreover, early
studies demonstrated that elevated adenosine signaling via
ADORA2B on erythrocytes stimulated 2,3-BPG production,
sickle hemoglobin deoxygenation, and subsequent sickling
(Sun et al., 2006; Zhang et al., 2011). Thus, prolonged adeno-
sine-ADORA2B signaling in SCDmice has at least two important
effects: induction of sickling by increasing 2,3-BPG levels in
erythrocytes and induction of a state of thermal and mechanical
hypersensitivity in nociceptors that involves upregulation of
TRPV1 expression and function. Overall, we have demonstrated
the sustained elevated circulating adenosine is a common factor
contributing to chronic pain by activating ADORA2B in Ada/
mice independent of sickling and in SCD mice with sickling.
Our finding of the critical role of sustained elevated circulating
adenosine signaling via ADORA2B in chronic pain is significant
because it immediately suggests lowering persistently elevated
adenosine by PEG-ADA or interfering with ADORA2B activation
are potential mechanistic-based therapies for chronic pain. In
particular, PEG-ADA is an FDA-approved drug that has been
used to treat ADA-deficient humans for more than 30 years.
Our preclinical evidence indicates that lowering adenosine by
PEG-ADA in SCD is a promising and relatively safe approach
to treat both sickling and chronic pain.
A particularly important finding was that pain-related behavior
induced by prolonged elevation of adenosine levels was not ex-
erted by direct action of adenosine on sensory neurons. Instead,
adenosine-induced pain behavior was produced by activating
ADORA2B in myeloid cells, possibly including microglial cells.
Although microglia are well recognized to promote local inflam-
mation and chronic pain (Basbaum et al., 2009; McMahon
et al., 2015), emerging evidence indicates that increasedCell Reports 16, 106–119, June 28, 2016 115
peripheral inflammatory responses contribute to chronic pain
(Chiu et al., 2012; McMahon et al., 2015). To determine the role
of myeloid cells in chronic inflammatory pain, we conducted ge-
netic studies showing that CFA-induced pain was significantly
reduced in Adora2bf/f/Lyz-Cre compared to Lyz-Cre mice. Lyz-
Cre is highly expressed by all myeloid cells, including microglia
(Clausen et al., 1999). It is possible that ADORA2B on microglia
may contribute to CFA-induced pain. To further assess whether
BMDCs play an important role in chronic pain in SCD mice, we
transplanted BMDCs from SCD mice into irradiated WT and
Adora2b/ mice. We found no significant difference in pain
behavior between irradiated WT and Adora2b/ mice trans-
planted with SCD BM. Several studies show the specific infiltra-
tion of monocyte-derived macrophages under pathological con-
ditions (Larochelle et al., 2016), including multiple sclerosis,
experimental autoimmune encephalomyelitis, or irradiation prior
to BMT. It is possible that ADORA2B positive SCD mouse
BMDCs of the myeloid lineage may infiltrate the CNS after irradi-
ation, differentiate into ADORA2B positive glia, and contribute to
the pain behavior observed in the Adora2b/ recipient mice.
Although our current experimental results do not allow us to
clearly distinguish between circulatingmonocytes andmicroglia,
we have provided considerable genetic and pharmacological ev-
idence that elevated circulating adenosine signaling via myeloid
cell ADORA2B (including microglial cells) contributes to chronic
inflammatory pain.
How does adenosine-ADORA2B signaling in BMDCs lead to
persistent hypersensitivity in nociceptors? Both Ada/ and
SCD mice exhibited elevated plasma levels of IL-6 and sIL-6R
that depended upon prolonged elevated blood adenosine-medi-
ated ADORA2B activation on myeloid cells. Moreover, neutral-
izing antibodies to IL-6 or gp130 blocked reflex hypersensitivity,
capsaicin responses, and TRPV1 upregulation. Combined with
the lack of detectable IL-6R expression or physiological re-
sponses to IL-6 in isolated DRG neurons, these results indicate
that an IL-6/sIL-6R complex transactivates gp130 on sensory
neurons to induce TRPV1 gene expression and sensory neuron
hypersensitivity in both conditions. In addition to a role for
myeloid cells, as shown here, mast cell activation has been
shown to promote pain-related inflammatory neuropathy in
SCD mice (Vincent et al., 2013). Interestingly, elevated adeno-
sine is known to activate mast cells and lead to trachea constric-
tion and respiratory obstruction in Ada/ mice (Zhong et al.,
2001). Moreover, ADORA2B activation can directly induce IL-8
secretion from cultured human mast cells (Feoktistov and Biag-
gioni, 1995). Adenosine signaling via ADORA2B may promote
pain by mast cell activation. Nevertheless, we have provided
both genetic and pharmacological evidence that prolonged
elevated adenosine signaling via ADORA2B on myeloid cells in-
duces a circulating IL-6-sIL-6R complex to transactivate gp130
on neuronal cells, resulting in increased TRPV1 gene expression
and function and chronic pain in both Ada/ and SCD mice.
The role of adenosine signaling and IL-6 trans-signaling in noci-
ception in both Ada/ and SCD mice is further validated in
another widely used inflammatory pain model, CFA injection. We
demonstrated that CFA injection caused elevated plasma adeno-
sine and IL-6 levels. Statistically significant elevation of adenosine
lasted at least 6 but less than 48 hr, which ismuch briefer than the116 Cell Reports 16, 106–119, June 28, 2016chronic elevation produced in Ada/ and SCD mice. Because
extracellular adenosine is degraded very rapidly and rarely re-
mains elevated in plasma for more than a few minutes, more
than 6 hr elevated adenosine with a single injection of CFA would
represent an unusually prolonged exposure of blood-borne cells
to this signalingmolecule. Selective genetic ablation of ADORA2B
on myeloid cells significantly attenuated the CFA-induced in-
crease of plasma IL-6, as well as reflex hypersensitivity, sensory
neuronhyperexcitability, and upregulation of TRPV1geneexpres-
sion in theseneurons.Notably, our finding is strongly supportedby
earlier studies showing plasma IL-6 induces pain-related behavior
by forming a complex with sIL-6R, which transactivates gp130 on
sensory neurons (Baastrup et al., 2014; Boettger et al., 2010).
However, the specific cell type and signaling cascade leading to
activation of IL-6-sIL-6R trans-signaling in chronic pain remained
unidentified. Here using three independent chronic pain mouse
models, we demonstrate that persistently elevated circulating
adenosine activates ADORA2B on myeloid cells, leading to IL-6
and sIL-6R trans-activation of gp130 on DRG neurons and result-
ing in increased TRPV1 gene expression and hypersensitivity and
chronic pain. Supporting the in vivo findings in both Ada/ SCD
and CFA-injected mice, we further demonstrated that IL-6 trans-
signaling via sIL-6R activates gp130, resulting in the translocaliza-
tion of pSTAT3 to nucleus and the induction of TRPV1 gene
expression in isolatedDRGneuronal cells fromWTmice. Although
DRG neurons contain no IL-6R, they can respond to IL-6 trans-
signaling via gp130 activation and contribute to chronic pain by
inducing TRPV1 in DRG neurons in a pSTAT3-dependent manner
(Figure 6C).
In summary, our studies lead to a workingmodel for the induc-
tionof persistent pain inwhichactivationof ADORA2Bonmyeloid
cells by prolonged exposure to adenosine in theblood causes the
release of IL-6 from these cells, transactivation of gp130 on noci-
ceptive sensory neurons by a sIL-6R/IL-6 complex, and a conse-
quent pSTAT3-mediated increase in the nociceptive function of
sensoryneurons that involvesenhancedTRPV1geneexpression.
These mechanistic findings suggest therapeutic approaches
for treating chronic pain including PEG-ADA (an FDA approved
drug), ADORA2B-specific antagonists, and inhibiting IL-6-sIL-
6R transactivation of gp130 in nociceptive sensory neurons.
EXPERIMENTAL PROCEDURES
Additional methods can be found in the Supplemental Information.
Animals
Ada/ mice were generated and genotyped as previously described (Black-
burn et al., 2000). Mice homozygous for the null Ada allele were designated
Ada/, whereas mice heterozygous for the null Ada allele were designated as
Ada/+. Ada//Adora2b/ mice were generated by mating Ada/ mice with
Adora2b/. Adora2bf/f-Lyz-Cre mice were generated by mating Adora2bf/f
with Lyz-Cre mice. Berkeley SCD transgenic mice were purchased from The
Jackson Laboratory. All studies were reviewed and approved by the University
of Texas Health Science Center at Houston Animal Welfare Committee.
Pharmacological Applications in Mice, Including Treatment with
PEG-ADA, Adenosine Receptor Antagonists, Neutralizing gp130Fc
Antibody, and Humanized IL-6 Neutralizing Antibody
PEG-ADA was generated by the covalent modification of purified bovine ADA
with activated PEG as described previously (Blackburn et al., 2000). Ada/
mice were maintained on high-dose (HD) enzyme therapy at 5U/week until
8 weeks to maintain viability (Mi et al., 2008). The Ada/ mice were divided
into five groups, each receiving a specific adenosine receptor antagonist,
except for controls that received PBS. For IL-6 antibody studies, mice were
divided into two groups. The first was injected IP with neutralizing IL-6 anti-
body or sgp130Fc (100 mg per day; R&D Systems) for 2 weeks (Le et al.,
2014). The second group was injected daily with PBS or IgG Fc for 2 weeks.
SCD mice at 8–14 weeks of age were divided into two groups and followed
the same procedures for Ada/ mice, except for the lower dosage of PEG-
ADA (2.5U per week), PSB1115 (200 mg per day; Tocris Bioscience), or
sgp130Fc (100 mg per day) for 2 weeks.
Mechanical and Thermal Hypersensitivity
All animals were acclimated to the behavioral testing apparatus. Each mouse
was placed in a clear Plexiglas testing chamber (8 3 8 3 12 cm) and accli-
mated prior to all experiments. To measure mechanical sensitivity, animals
were placed on an elevated wire grid and the left hind-paw was probed with
calibrated von Frey filaments (0.02–0.4g bending forces, North Coast). To
measure heat hypersensitivity, mice were placed on a glass plate (Plantar
Analgesia meter; IITC), and a radiant heat source was applied to the plantar
surface of a hind-paw. The tests and data analysis were conducted in a
double-blind fashion.
Neuronal Excitability Tests
DRGs were isolated from 3–6 mice per group. Depending on the number of
mice per group, we recorded an optimal number of around 36–60 neurons
for patch-clamp studies. About 80% of the series resistance was compen-
sated electronically. Membrane potentials were recorded using an Axopatch
200B amplifier (Axon Instruments) in response to series of 500-ms current
injections (except where noted). Signals were digitized with a Digidata
1440A A/D converter at 10 kHz, filtered at 2 kHz, and analyzed using Clampfit
10 software (Molecular Devices).
Statistical Analysis
All data are expressed as mean ± SEM. Data were analyzed for statistical sig-
nificance using GraphPad Prism 4 software (GraphPad Software). Student’s
t tests (paired or unpaired as appropriate) were applied in two-group analysis.
Differences among the means of multiple groups were compared by the one-
way ANOVA. Moreover, two-way ANOVA was used for difference among the
means ofmultiple groups for Figures 4A and 4E, and two-way repeatmeasures
ANOVA was used for difference among the means of multiple groups at
different time points for Figures 5A–5F, followed by a Tukey’smultiple compar-
isons test. A value of p < 0.05was considered significant andwas the threshold
to reject the null hypothesis.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2016.05.080.
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